P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes. 2020

Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
1School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin Road, Qixia District, Nanjing, 210023 Jiangsu China.

The increasing prevalence of depression and diabetes mellitus has become a major public health problem worldwide. Studies have shown that people with diabetes are at a high risk of being diagnosed with depression, and diabetes complicates depression treatment by promoting the deterioration of glycemic control, reducing self-care ability and quality of life, and causing severe functional disability and early mortality. Moreover, health deterioration dramatically increases the financial cost of social and health care system. Thus, how to treat depression, diabetes, and diabetes complicated by depression has become one of the world's urgent concerns. The activation of nod-like receptor family pyrin domain containing 3 (NLRP3) is closely related to mental illness. This finding provides a new perspective for studying depression. NLRP3 plays an important role in the development of diabetes. In this review, we elaborate the definition and epidemiology of depression, diabetes, and diabetic depression and introduce the functional characteristics of an NLRP3 inflammasome and upstream P2X7 receptor. Moreover, related research on NLRP3 inflammasomes and P2X7 receptors is summarized and used as a reference for confirming that the excessive activation of P2X7- NLRP3 leads to the increased release of inflammatory cytokines, such as IL-1β, in depression and diabetes. We provide insights into the P2X7-NLRP3-IL-1β pathway as an important pathological mechanism and novel therapeutic target in diabetes and depression. Given that the P2X7-NLRP3-IL-1β pathway may play an important role in diabetes confounded by comorbid depression, the possibility of intervention with baicalin is proposed.

UI MeSH Term Description Entries

Related Publications

Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
July 2017, Oncotarget,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
February 2017, The Journal of experimental medicine,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
August 2023, Progress in neuro-psychopharmacology & biological psychiatry,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
January 2017, Frontiers in immunology,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
May 2021, Biochemical pharmacology,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
June 2019, Nature communications,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
November 2020, Cell reports,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
January 2023, Ecotoxicology and environmental safety,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
May 2018, The Journal of infectious diseases,
Danwen Wang, and Hui Wang, and Haixia Gao, and Heng Zhang, and Hua Zhang, and Qiuling Wang, and Zhiling Sun
January 2013, Journal of leukocyte biology,
Copied contents to your clipboard!